Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, has appointed Christiane Bardroff as chief operating officer (COO), effective December 1, 2022.
 
With this expansion of its Executive Board, Rentschler Biopharma is strengthening its focus on its core operations to ensure it delivers the highest quality products and services to its clients and partners. Bardroff will head clinical and commercial manufacturing, engineering and technology operations, as well as production automation, and will lead a highly competent, dedicated and agile team.

Experience

With more than 15 years of experience in the biopharmaceutical industry, mainly in large corporations, with a focus on operations and automation, including overall responsibility for the construction of new biotechnology plants, Bardroff brings extensive knowledge to her position.
 
She has applied her experience as part of global leadership teams and has always been committed to employee advancement and development. Over the past few months, the Supervisory Board has been impressed by how successfully Bardroff has contributed to Rentschler Biopharma as senior vice president (SVP) Client Program Management, as well as SVP Clinical and Commercial Manufacturing.
 
Prof. Dr. Nikolaus F. Rentschler, chairman of the Supervisory Board of Rentschler Biopharma SE, said: “Our goal at Rentschler is to create value sustainably and to reliably provide premium services to our clients. During the past months, Christiane Bardroff has impressively demonstrated that she fully shares our values and aspirations. With her appointment to the Executive Board and her strong experience, we will heighten our focus on operational processes around the production of innovative and complex biopharmaceuticals. She is an engaging and inspiring addition to our Executive Board team.”
 
“Christiane is an experienced manager and an outstanding leader who has already achieved a lot since joining Rentschler Biopharma earlier this year. In recent months, she has exhibited her talent and abilities by implementing several important changes and continually motivating the team. It is a great pleasure to have her become COO,” commented Dr. Frank Mathias, CEO of Rentschler Biopharma.
 
Bardroff added: “I am very happy to be part of the Rentschler team and consider it a true privilege to work with such great colleagues. The employees at all three of our sites – Laupheim, Milford and Stevenage – bring a high level of commitment, cooperation, and expertise, working together with our partners to deliver the best results for our clients. Rentschler is an impressive organization with its long-standing history as a family-owned CDMO, as well as its vast range of complex products, its creativity in meeting the different needs of its many clients and its extensive know-how and flexibility in finding innovative solutions. By actively listening, having a positive mindset and bringing together diverse experiences, I want to inspire people and create a sustainable environment of trust, in order to contribute to the greater good. I look forward to this exciting challenge.”
 
Bardroff joined Rentschler Biopharma as SVP Client Program Management in February 2022 and, since May 2022, has also been SVP Clinical and Commercial Manufacturing at the Laupheim site.
 
Previously, she was responsible for the construction of Teva Biotech’s highly automated, large-scale biotechnology production facility in Ulm, Germany. In this role, she led the site leadership team and was part of Teva Biotech’s global leadership team as well. During her many years at Roche, she gained strong experience in the production of various biotechnology products, as well as in automation, IT and project management.
 
Bardroff studied biotechnology and chemical engineering at Emden University of Applied Sciences, Germany and Zhejiang University of Science and Technology in Hangzhou, China.